Small-cell lung cancer patients are just 'a little bit' tired: response shift and self-presentation in the measurement of fatigue

被引:35
|
作者
Westerman, Marjan J.
The, Anne-Mei
Sprangers, Mirjam A. G.
Groen, Harry J. M.
van der Wal, Gerrit
Hak, Tony
机构
[1] VU Univ, Ctr Med, Dept Publ & Occupat Hlth, EMGO Inst, NL-1081 BT Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Psychol Med, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Groningen Hosp, Dept Pulm Dis, Groningen, Netherlands
[4] Erasmus Univ, RSM, Rotterdam, Netherlands
关键词
small-cell lung cancer; quality of life; response shift; self-presentation; fatigue;
D O I
10.1007/s11136-007-9178-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Response shift has gained increasing attention in the measurement of health-related quality of life (QoL) as it may explain counter-intuitive findings as a result of adaptation to deteriorating health. Objective To search for response shift type explanations to account for counter-intuitive findings in QoL measurement. Methods Qualitative investigation of the response behaviour of small-cell lung cancer (SCLC) patients (n = 23) in the measurement of fatigue with The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) question 'were you tired'. Interviews were conducted at four points during 1st line chemotherapy: at the start of chemotherapy, 4 weeks later, at the end of chemotherapy, and 6 weeks later. Patients were asked to 'think aloud' when filling in the questionnaire. Results Fifteen patients showed discrepancies between their answer to the EORTC question 'were you tired' and their level of fatigue spontaneously reported during the interview. These patients chose the response options 'not at all' or 'a little' and explained their answers in various ways. In patients with and without discrepancies, we found indications of recalibration response shift (e.g. using a different comparison standard over time) and of change in perspective (e.g. change towards a more optimistic perspective). Patients in the discrepancy group reported spontaneously how they dealt with diagnosis and treatment, i.e. by adopting protective and assertive behaviour and by fighting the stigma. They distanced themselves from the image of the stereotypical cancer patient and presented themselves as not suffering and accepting fatigue as consequence of treatment. Conclusion In addition to response shift, this study suggests that 'self-presentation' might be an important mechanism affecting QoL measurement, particularly during phases when a new equilibrium needs to be found.
引用
收藏
页码:853 / 861
页数:9
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF PLATIN IN PATIENTS WITH SMALL-CELL LUNG-CANCER
    KULIK, GI
    SOLYANIK, GI
    LIPOVOY, AS
    BAGIRYAN, MA
    BIRYUK, LI
    VOPROSY ONKOLOGII, 1991, 37 (05) : 568 - 571
  • [22] Trends in response rate and survival in small-cell lung cancer patients between 1997 and 2017
    Lattuca-Truc, Mickael
    Timsit, Jean-Francois
    Levra, Matteo Giaj
    Ruckly, Stephane
    Villa, Julie
    Dumas, Isabelle
    Pinsolle, Julian
    Ferrer, Leonie
    Guillem, Pascale
    Moro-Sibilot, Denis
    Toffart, Anne-Claire
    LUNG CANCER, 2019, 131 : 122 - 127
  • [23] A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer
    Shibayama, Takuo
    Hotta, Katsuyuki
    Takigawa, Nagio
    Tada, Atsuhiko
    Ueoka, Hiroshi
    Harita, Shingo
    Kiura, Katsuyuki
    Tabata, Masahiro
    Segawa, Yoshihiko
    Nogami, Naoyuki
    Kuyama, Shoichi
    Shinkai, Tetsu
    Tanimoto, Mitsune
    LUNG CANCER, 2006, 53 (02) : 189 - 195
  • [24] Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer
    Garst, Jennifer
    Buller, Richard
    Lane, Stephen
    Crawford, Jeffrey
    CLINICAL LUNG CANCER, 2005, 7 (03) : 190 - 196
  • [25] Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
    Kukec, Renata Rezonja
    Grabnar, Iztok
    Vovk, Tomaz
    Mrhar, Ales
    Kovac, Viljem
    Cufer, Tanja
    RADIOLOGY AND ONCOLOGY, 2015, 49 (02) : 173 - 180
  • [26] Small-cell Lung Cancer in Very Elderly (≥ 80 Years) Patients
    Schild, Steven E.
    Zhao, Liming
    Wampfler, Ason A.
    Daniels, Thomas B.
    Sio, Terence
    Ross, Helen J.
    Paripati, Harshita
    Marks, Randolph S.
    Yi, Joanne
    Liu, Han
    He, Yanqi
    Yang, Ping
    CLINICAL LUNG CANCER, 2019, 20 (04) : 313 - 321
  • [27] ACTIVATION OF THE HEMOSTATIC SYSTEM IN PATIENTS WITH SMALL-CELL LUNG-CANCER
    MILROY, R
    DOUGLAS, JT
    LOWE, GDO
    BANHAM, SW
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1986, 69 : A109 - A109
  • [28] The importance of haematological toxicity on outcomes of small-cell lung cancer patients
    Araujo, A.
    Pousa, E.
    Soares, M.
    Azevedo, I.
    Velosa, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 544 - 544
  • [29] ORAL IFOSFAMIDE AND ETOPOSIDE FOR SMALL-CELL LUNG-CANCER PATIENTS
    LIND, M
    THATCHER, N
    CERNY, T
    CARROLL, K
    BRITISH JOURNAL OF CANCER, 1987, 55 (03) : 338 - 338
  • [30] Selective suppression of cytokine secretion in patients with small-cell lung cancer
    Fischer, JR
    Schindel, M
    Stein, N
    Lahm, H
    Gallati, H
    Krammer, PH
    Drings, P
    ANNALS OF ONCOLOGY, 1995, 6 (09) : 921 - 926